When applied in concentrations ranging from 10 to 40 μΜ over a period of 1 to 7 days, Remodelin systematically diminishes NAT10 activity and cell growth in a concentration-responsive manner across both AR-positive and AR-negative prostate cancer cell types^[2].

At a dosage of 20 μΜ for a duration of 24 hours, it specifically reduces NAT10 activity and decelerates DNA synthesis in prostate cancer cells^[2].

Moreover, a 7-day treatment with Remodelin at 1 μΜ lessens nuclear abnormalities and bolsters genomic integrity in LmnaG609G/G609G fibroblasts^[3].

Intraperitoneal injection (i.p.), once every two days for 4 weeks, Remodelin significantly reduced AR-negative prostate cancer tumor growth in PC-3 cells tumor xenograft model in nude athymic BALB/c nu/nu mice^[2].